Fate’s #ACR2026 studies suggest #iPSC-derived #CARTs could become a compelling allogeneic platform: a potentially unlimited supply of a standardized, homogeneous product. Data cover FT819 in lupus - without conditioning/outpatient use - and CD19/CD38 FT839 in RA.
@jdevos.bsky.social